Scholars@Duke
Vern Charles Juel

Vern Charles Juel

Professor of Neurology
Neurology, Neuromuscular Disease
Duke Box 3403, Durham, NC 27710
1255 Hospital South, Durham, NC

Scholarly Works - Conferences

The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

Conference Muscle Nerve · May 2026 INTRODUCTION/AIMS: Azathioprine (AZA) and mycophenolate mofetil (MMF) are the most commonly used non-steroidal immunosuppressants in patients with generalized myasthenia gravis (gMG) in North America but their relative effectiveness among disease subgroups ... Full text Link to item Cite

Pregnancy in MuSK-positive myasthenia gravis: A single-center case series.

Conference Muscle Nerve · July 2023 INTRODUCTION/AIMS: Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. Our objective in this study was to describe the course of MMG during pregnancy and within 6 months po ... Full text Link to item Cite

The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes.

Conference Muscle Nerve · April 2023 INTRODUCTION/AIMS: The Duke Myasthenia Gravis (MG) Clinic Registry contains comprehensive physician-derived data on patients with MG seen in the Duke MG Clinic since 1980. The aim of this study was to report outcomes in patients seen in the clinic and trea ... Full text Link to item Cite

Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis: follow up survey

Conference RRNMF Neuromuscular Journal · February 7, 2023 Introduction  We previously conducted a survey study in April 2020 at the beginning of the SARS-CoV-2 (COVID-19) pandemic to understand how it affected patients with myasthenia gravis (MG). Since then, significant advances have occurred in th ... Full text Open Access Cite

Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.

Conference CPT Pharmacometrics Syst Pharmacol · September 2017 Lambert-Eaton myasthenia (LEM) is a rare autoimmune disorder associated with debilitating muscle weakness. There are limited treatment options and 3,4-diaminopyridine (3,4-DAP) free base is an investigational orphan drug used to treat LEM-related weakness. ... Full text Link to item Cite

INCREASED OCCURRENCE OF LATE ONSET MYASTHENIA GRAVIS

Conference MUSCLE & NERVE · October 1, 2011 Link to item Cite